专利：获授权中国专利 4 项
奖励荣誉：
1.江苏省医学新技术引进奖一等奖
2.南京市医学新技术引进奖二等奖
承担科研项目 7 项；发表论文 60 篇，其中SCI 28 篇；主编教材 1 部，参编教材 4 部
代表性论文
1、Zhan Shi , Ju Yang , Weiwei Kong , Xin Qiu , Changchang Lu , Juan Liu ,Baorui Liu and Juan Du Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
Front. Oncol， 12:782730
2、Jie Shao, Qin Liu , Jie Shen, Xiaoping Qian, Jing Yan, Yahui Zhu, Xin Qiu,Changchang Lu, Lanqi Cen, Manman Tian, Juan Du and Baorui Liu Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
Front. Immunol，13:799026
3、Juan Du, Xin Qiu, Changchang Lu, Yahui Zhu, Weiwei Kong, Mian Xu, Xin Zhang, Min Tang, Jun Chen, Qi Li, Aimei Li, Jian He, Qing Gu, Lei Wang, Yudong Qiu and Baorui Liu Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy Front. Oncol，12:844527，May 2022
4、Changchang Lu, Yahui Zhu, Hao Cheng, Weiwei Kong, Linxi Zhu, Lei Wang, Min Tang, Jun Chen, Qi Li, Jian He, Aimei Li, Xin Qiu, Dongsheng Chen, Fanyan Meng, Xiaoping Qian, Baorui Liu, Yudong Qiu and Juan Du Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer Front. Oncol，12:898119. June 2022
5、Changchang Lu, Yahui Zhu, Weiwei Kong, Ju Yang, Linxi Zhu, Lei Wang, Min Tang, Jun Chen, Qi Li, Jian He,Aimei Li, Xin Qiu, Qing Gu, Dongsheng Chen,Fanyan Meng, Baorui Liu , Yudong Qiu and Juan Du Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer. Front Oncol. 2022 Aug 18;12:879661.
6、Juan Du, Linxi Zhu, Huizi Sha, Zhengyun Zou, Jie Shen,Weiwei Kong, Lianjun Zhao, Qing Gu, Lixia Yu, Yudong Qiu, Baorui Liu Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in the treatment of unresectable pancreatic cancerFront Oncol. 2022 Nov 1;12:1015232.
7、Gong X, Zhu Y, Zhang Q, Qiu X, Lu C, Tong F, Wang Q, Kong W, Zhou H, Liu B, Zhou Y, Du J.Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort Hum Vaccin Immunother. 2022 Nov 30;18(6):2143154.
8、Wangshu Dai, Xin Qiu, Changchang Lu, Zhengyun Zou, Huizi Sha, Weiwei Kong, Baorui Liu and Juan Du. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study.Front Oncol. 2021 Oct 13;11:693386.
9、Du J, Su S, Li H, Shao J, Meng F, Yang M, Qian H, Zou Z, Qian X, Liu B. Low dose irradiation increases adoptive cytotoxic T lymphocyte migration in gastric cancer, Exp Ther Med. 2017 Dec;14(6):5711-5716.
代表性教材与专著
1、答“胰”解惑——专家谈胰腺癌那些事，2022年2、肿瘤个体化与靶向免疫治疗学 科学出版社 20173、Personalized Management of Gastric Cancer Translational and Precision Medicine Springer 出版社 2017